Highlights MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
38.43 ^USD	-2.68%		-7.20%	-36.36%

10/06	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from Both FDA and EMA on Path for the Phase 3 Program for the Nanobody Sonelokimab in Psoriatic Arthritis	CI
07/05	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from Both FDA and EMA on Path for the Phase 3 Program for the Nanobody Sonelokimab in Psoriatic Arthritis	11/06	CI
MoonLake Immunotherapeutics Q1 Net Loss Widens	07/05	MT
MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment	10/04	MT
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	12/03	DJ
MoonLake Immunotherapeutics Announces Significant Improvements with Nanobody Sonelokimab over 24 Weeks in Active Psoriatic Arthritis	10/03	CI
Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024	04/03	CI
MoonLake Immunotherapeutics Shares Decline After Posting Q4 Loss	29/02	MT
MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02	CI
MoonLake Gains FDA, EMA Backing For Late-Stage Hidradenitis Suppurativa Trial	26/02	MT
MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
MoonLake Immunotherapeutics Announces Landmark Phase 2 Results for Nanobody Sonelokimab in Active Psoriatic Arthritis	05/11	CI
MoonLake Immunotherapeutics Stock Up 13% on Positive Data for Skin Condition Treatment	16/23/16	DJ
MoonLake Immunotherapeutics Announces the Full Dat Datasets from its 24-Week MIRA Clinical Trial, Establishing the Nanobody(R) Sonelokimab as Highly Promanded Therapeutics for Hidradenitis Suppurativa	15/23/15	CI
Moonlake Immunotherapeutics Ag Announces Phase 2 Mira Primary Analysis Trial Results for Nanobody®? Sonelokimab in Hidradenitis Suppurativa to Be Presented At the European Academy of Dermatology and Venereology Congress	04/23/04	CI
MoonLake Immunotherapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
MoonLake Immunotherapeutics explores sale-sources	15/23/15	RE
MOONLAKE IMMUNOTHERAPEUTICS WORKING WITH AN INVESTMENT…	15/23/15	RE
MoonLake Immunotherapeutics Achieves Landmark Milestone with Positive Phase 2 Results for Nanobody(R) Sonelokimab in Hidradenitis Suppurativa	25/23/25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Highlights

Filters